ICON Public Limited Company (ICLR)
USD 142.96
(-1.55%)
USD 142.96
(-1.55%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.74 Billion USD | -10.8% |
| 2022 | 8.68 Billion USD | -6.79% |
| 2021 | 9.32 Billion USD | 487.98% |
| 2020 | 1.58 Billion USD | 22.93% |
| 2019 | 1.28 Billion USD | 28.95% |
| 2018 | 999.97 Million USD | 4.64% |
| 2017 | 955.61 Million USD | 8.51% |
| 2016 | 880.66 Million USD | -7.76% |
| 2015 | 954.7 Million USD | 65.29% |
| 2014 | 577.58 Million USD | 8.59% |
| 2013 | 531.88 Million USD | 21.23% |
| 2012 | 438.73 Million USD | 23.96% |
| 2011 | 353.92 Million USD | 26.61% |
| 2010 | 279.53 Million USD | -16.84% |
| 2009 | 336.15 Million USD | -18.2% |
| 2008 | 410.91 Million USD | 35.42% |
| 2007 | 303.43 Million USD | 75.92% |
| 2006 | 172.48 Million USD | 61.78% |
| 2005 | 106.61 Million USD | -10.08% |
| 2004 | 118.56 Million USD | 20.85% |
| 2003 | 98.1 Million USD | 68.47% |
| 2002 | 58.23 Million USD | 37.38% |
| 2001 | 42.38 Million USD | 83.77% |
| 2000 | 23.06 Million USD | -1.85% |
| 1999 | 23.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.61 Billion USD | -1.72% |
| 2024 Q3 | 7.43 Billion USD | 0.72% |
| 2024 Q2 | 7.38 Billion USD | -3.04% |
| 2023 Q2 | 8.31 Billion USD | -3.72% |
| 2023 FY | 7.74 Billion USD | -10.8% |
| 2023 Q1 | 8.63 Billion USD | -0.63% |
| 2023 Q4 | 7.74 Billion USD | -4.01% |
| 2023 Q3 | 8.07 Billion USD | -2.87% |
| 2022 Q3 | 8.88 Billion USD | -0.04% |
| 2022 FY | 8.68 Billion USD | -6.79% |
| 2022 Q1 | 9.09 Billion USD | -2.43% |
| 2022 Q2 | 8.89 Billion USD | -2.23% |
| 2022 Q4 | 8.68 Billion USD | -2.25% |
| 2021 FY | 9.32 Billion USD | 487.98% |
| 2021 Q1 | 1.53 Billion USD | -3.33% |
| 2021 Q2 | 1.55 Billion USD | 1.57% |
| 2021 Q3 | 9.68 Billion USD | 522.28% |
| 2021 Q4 | 9.32 Billion USD | -3.78% |
| 2020 Q2 | 1.28 Billion USD | -3.56% |
| 2020 Q1 | 1.32 Billion USD | 2.95% |
| 2020 Q3 | 1.35 Billion USD | 5.78% |
| 2020 Q4 | 1.58 Billion USD | 17.05% |
| 2020 FY | 1.58 Billion USD | 22.93% |
| 2019 Q4 | 1.28 Billion USD | 3.75% |
| 2019 FY | 1.28 Billion USD | 28.95% |
| 2019 Q3 | 1.24 Billion USD | 1.61% |
| 2019 Q1 | 1.18 Billion USD | 18.51% |
| 2019 Q2 | 1.22 Billion USD | 3.21% |
| 2018 Q1 | 1.01 Billion USD | 6.16% |
| 2018 FY | 999.97 Million USD | 4.64% |
| 2018 Q4 | 999.97 Million USD | 0.88% |
| 2018 Q3 | 991.24 Million USD | 5.93% |
| 2018 Q2 | 935.74 Million USD | -7.76% |
| 2017 Q1 | 910.7 Million USD | 3.41% |
| 2017 FY | 955.61 Million USD | 8.51% |
| 2017 Q4 | 955.61 Million USD | 3.22% |
| 2017 Q3 | 925.79 Million USD | 5.84% |
| 2017 Q2 | 874.71 Million USD | -3.95% |
| 2016 FY | 880.66 Million USD | -7.76% |
| 2016 Q1 | 952.45 Million USD | -0.24% |
| 2016 Q2 | 840.27 Million USD | -11.78% |
| 2016 Q3 | 908.61 Million USD | 8.13% |
| 2016 Q4 | 880.66 Million USD | -3.08% |
| 2015 Q3 | 949.52 Million USD | 54.64% |
| 2015 FY | 954.7 Million USD | 65.29% |
| 2015 Q2 | 614.04 Million USD | 1.39% |
| 2015 Q1 | 605.63 Million USD | 4.86% |
| 2015 Q4 | 954.7 Million USD | 0.55% |
| 2014 Q3 | 561.56 Million USD | 6.48% |
| 2014 FY | 577.58 Million USD | 8.59% |
| 2014 Q1 | 523.75 Million USD | -1.53% |
| 2014 Q4 | 577.58 Million USD | 2.85% |
| 2014 Q2 | 527.4 Million USD | 0.7% |
| 2013 Q2 | 491.41 Million USD | 6.07% |
| 2013 FY | 531.88 Million USD | 21.23% |
| 2013 Q4 | 531.88 Million USD | 4.79% |
| 2013 Q3 | 507.54 Million USD | 3.28% |
| 2013 Q1 | 463.28 Million USD | 3.52% |
| 2012 FY | 438.73 Million USD | 23.96% |
| 2012 Q1 | 423.73 Million USD | 19.72% |
| 2012 Q4 | 447.53 Million USD | 7.53% |
| 2012 Q3 | 416.18 Million USD | -1.21% |
| 2012 Q2 | 421.29 Million USD | -0.58% |
| 2011 Q1 | 320.56 Million USD | 14.68% |
| 2011 FY | 353.92 Million USD | 26.61% |
| 2011 Q4 | 353.92 Million USD | 1.64% |
| 2011 Q3 | 348.21 Million USD | 15.13% |
| 2011 Q2 | 302.44 Million USD | -5.65% |
| 2010 Q2 | 270.66 Million USD | -13.28% |
| 2010 Q4 | 279.53 Million USD | -3.84% |
| 2010 FY | 279.53 Million USD | -16.84% |
| 2010 Q1 | 312.12 Million USD | -7.15% |
| 2010 Q3 | 290.69 Million USD | 7.4% |
| 2009 Q2 | 389.55 Million USD | 3.56% |
| 2009 FY | 336.15 Million USD | -18.2% |
| 2009 Q1 | 376.14 Million USD | -8.46% |
| 2009 Q3 | 381.28 Million USD | -2.12% |
| 2009 Q4 | 336.15 Million USD | -11.84% |
| 2008 Q2 | 394.97 Million USD | 5.27% |
| 2008 Q3 | 354.56 Million USD | -10.23% |
| 2008 FY | 410.91 Million USD | 35.42% |
| 2008 Q1 | 375.21 Million USD | 23.66% |
| 2008 Q4 | 410.91 Million USD | 15.89% |
| 2007 FY | 303.43 Million USD | 75.92% |
| 2007 Q1 | 155.11 Million USD | -10.07% |
| 2007 Q4 | 303.43 Million USD | 12.15% |
| 2007 Q3 | 270.56 Million USD | 47.62% |
| 2007 Q2 | 183.28 Million USD | 18.16% |
| 2006 Q1 | 110 Million USD | -1.82% |
| 2006 FY | 172.48 Million USD | 61.78% |
| 2006 Q3 | 145.79 Million USD | 19.24% |
| 2006 Q4 | 172.48 Million USD | 18.3% |
| 2006 Q2 | 122.26 Million USD | 11.15% |
| 2005 Q1 | 134.07 Million USD | 0.45% |
| 2005 FY | 106.61 Million USD | -10.08% |
| 2005 Q4 | 112.03 Million USD | 4.69% |
| 2005 Q3 | 107.01 Million USD | -5.8% |
| 2005 Q2 | 113.6 Million USD | -15.27% |
| 2004 Q3 | 117.97 Million USD | -0.5% |
| 2004 Q2 | 118.56 Million USD | 4.85% |
| 2004 Q1 | 113.08 Million USD | -0.0% |
| 2004 FY | 118.56 Million USD | 20.85% |
| 2004 Q4 | 133.46 Million USD | 13.13% |
| 2003 Q1 | 88.69 Million USD | 29.56% |
| 2003 Q3 | 94.78 Million USD | -3.39% |
| 2003 FY | 98.1 Million USD | 68.47% |
| 2003 Q4 | 113.08 Million USD | 19.31% |
| 2003 Q2 | 98.1 Million USD | 10.61% |
| 2002 FY | 58.23 Million USD | 37.38% |
| 2002 Q4 | 68.45 Million USD | 26.68% |
| 2002 Q3 | 54.04 Million USD | -7.2% |
| 2002 Q2 | 58.23 Million USD | 15.29% |
| 2002 Q1 | 50.51 Million USD | -2.81% |
| 2001 Q1 | 31.86 Million USD | 2.69% |
| 2001 Q4 | 51.97 Million USD | 26.36% |
| 2001 FY | 42.38 Million USD | 83.77% |
| 2001 Q3 | 41.13 Million USD | -2.96% |
| 2001 Q2 | 42.38 Million USD | 33.02% |
| 2000 Q1 | 30.7 Million USD | 15.44% |
| 2000 Q4 | 31.02 Million USD | -17.54% |
| 2000 Q3 | 37.62 Million USD | 63.13% |
| 2000 Q2 | 23.06 Million USD | -24.89% |
| 2000 FY | 23.06 Million USD | -1.85% |
| 1999 Q4 | 26.6 Million USD | 11.3% |
| 1999 FY | 23.5 Million USD | 0.0% |
| 1999 Q2 | 23.5 Million USD | 0.0% |
| 1999 Q3 | 23.9 Million USD | 1.7% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -19163.959% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -88167.164% |
| Aspira Women's Health Inc. | 8.62 Million USD | -89724.041% |
| Biodesix, Inc. | 94.51 Million USD | -8098.739% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -444755.48% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -230097.157% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -230097.157% |
| Bionano Genomics, Inc. | 118.24 Million USD | -6453.333% |
| CareDx, Inc | 223.28 Million USD | -3370.475% |
| Check-Cap Ltd. | 1.33 Million USD | -582540.602% |
| Castle Biosciences, Inc. | 86.54 Million USD | -8854.173% |
| DarioHealth Corp. | 38.24 Million USD | -20161.786% |
| Exact Sciences Corporation | 3.32 Billion USD | -132.984% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -5442.093% |
| Guardant Health, Inc. | 1.62 Billion USD | -376.067% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | -336.473% |
| Illumina, Inc. | 4.36 Billion USD | -77.488% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -138384.171% |
| iSpecimen Inc. | 6.07 Million USD | -127393.312% |
| Standard BioTools Inc. | 159.86 Million USD | -4747.29% |
| MDxHealth SA | 121.92 Million USD | -6255.697% |
| 23andMe Holding Co. | 206.64 Million USD | -3649.931% |
| Medpace Holdings, Inc. | 1.09 Billion USD | -605.827% |
| Myriad Genetics, Inc. | 312.9 Million USD | -2376.548% |
| Mainz Biomed B.V. | 12.15 Million USD | -63627.353% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -707480.74% |
| NeoGenomics, Inc. | 739.69 Million USD | -947.614% |
| Neogen Corporation | 1.44 Billion USD | -438.127% |
| Inotiv, Inc. | 588.04 Million USD | -1217.788% |
| Natera, Inc. | 691.79 Million USD | -1020.142% |
| OPKO Health, Inc. | 622.47 Million USD | -1144.881% |
| Psychemedics Corporation | 6.59 Million USD | -117346.499% |
| Prenetics Global Limited | 44.01 Million USD | -17506.336% |
| Prenetics Global Limited | 44.01 Million USD | -17506.336% |
| Precipio, Inc. | 3.67 Million USD | -210932.68% |
| Personalis, Inc. | 95.65 Million USD | -8000.859% |
| RadNet, Inc. | 2.07 Billion USD | -273.752% |
| Sera Prognostics, Inc. | 25.28 Million USD | -30549.527% |
| Sotera Health Company | 2.68 Billion USD | -188.427% |
| Neuronetics, Inc. | 81.64 Million USD | -9391.701% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -35651.419% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -35651.419% |
| Trinity Biotech plc | 83.38 Million USD | -9193.294% |
| Twist Bioscience Corporation | 152.97 Million USD | -4965.744% |
| Exagen Inc. | 34.25 Million USD | -22525.168% |